Benzinga | Nov 30, 2021 04:49PM EST

Clarus Therapeutics Announces Issuance Of 2 New Patents For JATENZO

Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that the United States Patent and Trademark Office (USPTO) has issued two new patents for claims that cover Clarus' oral testosterone replacement product, JATENZO (testosterone undecanoate).

Patent No. 11,179,403 entitled "Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same" and patent No. 11,179,402 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" both cover Clarus' approved product JATENZO. The new patents will expire in 2030 and 2026, respectively.

"These new patents broaden the patent estate for our lead commercial asset, JATENZO, and will bring the total number of patents listed in FDA's Orange Book to seven," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus and founder of its wholly-owned operating subsidiary, Clarus Therapeutics, Inc. "We believe these new patents serve to reinforce the already strong intellectual property portfolio for JATENZO as we continue our focus on current life cycle management programs and those planned for the future."